Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Sep 24, 2026
REX-Osprey SOL + Staking ETF (SSK) Delivers +17% Over 30 Days and +55% Quarterly

REX-Osprey SOL + Staking ETF (SSK) Delivers +17% Over 30 Days and +55% Quarterly

Key Takeaways

  • SSK gained roughly 17% over the trailing 30 days, climbing from about $13.24 to near $15.51 per share.
  • Over the past quarter, the fund has rallied more than 55%, rebounding sharply from its 52-week low of $8.37 set in early June.
  • SSK is the first U.S.-listed ETF offering native staking rewards on Solana (SOL), so its returns are overwhelmingly a function of SOL's spot price.
  • Staking income, paid to shareholders as monthly distributions, adds a supplementary return layer on top of price movement.
  • As a non-diversified, single-asset crypto ETF, SSK carries elevated concentration and volatility risk relative to broad-market funds.

Understanding the REX-Osprey SOL + Staking ETF (SSK) and Its Exposure

The REX-Osprey SOL + Staking ETF (SSK) is an actively managed exchange-traded fund that seeks to deliver roughly 1x the price performance of Solana, plus staking rewards generated by the network's proof-of-stake mechanism. Launched in July 2025, it was the first U.S.-listed fund to offer native, on-chain staking of Solana through a traditional ETF wrapper, with rewards distributed to investors in cash on a periodic basis rather than requiring holders to delegate or manage staking infrastructure themselves.

The portfolio is highly concentrated, typically holding only a handful of positions. Solana tokens themselves generally represent about half of net assets, with a meaningful secondary allocation to the CoinShares Physical Staked Solana product and a smaller position in JitoSOL, a liquid staking token on the Solana network, alongside a modest cash and government money-market allocation for operational liquidity. The fund carries a gross expense ratio of 0.75%. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the industry.

Because SSK is non-diversified and essentially a single-asset vehicle, its price is a near one-to-one reflection of Solana's spot price. There is little internal diversification to cushion drawdowns or dampen rallies, which explains both the fund's sharp gains and its pronounced volatility.

SSK's Price Action Over the Past Month and Quarter

Over the trailing 30 days, SSK advanced approximately +17%, moving from roughly $13.24 to near $15.51. The advance was not a straight line; the fund experienced several multi-day pullbacks interspersed with sharp, high-volume upswings, consistent with a trend-driven but volatile digital-asset market.

The longer three-month picture is even more pronounced. After sliding through a difficult June that took the fund to a 52-week low of $8.37, SSK staged a powerful recovery, gaining more than 55% over the quarter to approach $15.50. This rebound transformed what had been a deeply negative stretch into one of the fund's strongest periods since inception, underscoring how quickly sentiment can shift in single-coin crypto products.

Key Drivers Behind the Recent 30-Day Gains

The primary driver of SSK's recent performance was a sustained rally in the underlying Solana token. Because the fund holds Solana either directly or through staked-SOL exposure, its net asset value (NAV) and market price track SOL closely. When SOL appreciates, SSK appreciates in near-lockstep, and the 30-day move reflects that concentrated linkage rather than stock-picking or sector diversification.

Staking rewards provided an additional, albeit secondary, contribution. The fund passes through native staking income as distributions, which adds a layer of return on top of spot-price appreciation. In a rising-tape environment for SOL, the combination of capital appreciation and staking yield reinforced total-return momentum.

Broader digital-asset market conditions also played a role. Improved risk appetite across the crypto complex lifted sentiment toward major proof-of-stake networks, and Solana's positioning as a high-throughput blockchain with an active decentralized-finance and payments ecosystem kept investor attention focused on the asset. The fund's concentrated structure amplified these effects, magnifying both the upside move and the intraday volatility observed throughout the period.

Factors Behind the Strong Quarterly Rebound

Over the trailing three months, SSK's trajectory was defined by a sharp recovery from its June lows. The initial weakness reflected a broad pullback in digital assets, which dragged Solana and, by extension, the fund's NAV well below prior levels. The subsequent rebound coincided with improving sentiment across the cryptocurrency market and renewed interest in Solana's ecosystem activity.

Longer-term sector rotation also mattered. As investors reassessed risk assets and alternative exposures, capital flowed back toward established layer-1 blockchains with meaningful on-chain usage. For SSK, this translated into a more-than-55% quarterly gain, with staking distributions compounding the recovery in spot prices. The fund's concentrated, single-asset design meant that the same structure that amplified the spring decline also powered the rapid rebound.

Exploring Broader Trends with Tickeron Tools

From what I see, tools like Tickeron’s AI Screener help surface comparable single-asset crypto funds and sector ETFs by scanning technical indicators, fundamentals, and AI signals across thousands of securities. I ran a few queries on it to benchmark SSK’s momentum against peers, which added useful context to the price and staking analysis. It is a practical way to complement manual review without replacing core due diligence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SSK

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


Momentum Indicator for SSK turns positive, indicating new upward trend

SSK saw its Momentum Indicator move above the 0 level on September 17, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator turned positive. In 18 of the 19 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for SSK just turned positive on September 21, 2026. Looking at past instances where SSK's MACD turned positive, the stock continued to rise in 8 of 9 cases over the following month. The odds of a continued upward trend are 89%.

Following a +17.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where SSK advanced for three days, in 56 of 64 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

The Aroon Indicator entered an Uptrend today. In 28 of 33 cases where SSK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for SSK moved out of overbought territory on September 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 similar instances where the indicator moved out of overbought territory. In 5 of the 5 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SSK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

SSK broke above its upper Bollinger Band on September 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Industry description

The investment seeks investment results of the performance, before fees and expenses, of Solana (“SOL” or the “Reference Asset”) plus staking rewards associated with the Reference Asset. The fund, under normal market conditions, invests at least 80% of its net assets (plus any borrowings for investment purposes) in the reference asset and other assets that provide exposure to the Reference Asset. It will invest directly or through the REX-OspreyTM SOL Subsidiary. The fund is non-diversified.
View a ticker or compare two or three
SSK
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Digitalcurrency

Category
Digital Assets
Address
ETF Opportunities Trust
Phone
N/A
Web
N/A
Interact to see
Advertisement
Kingsoft Cloud Holdings Limited (KC) shares plunged about 9% in the most recent session, extending a sharp pullback after a recent rally. The selloff reflects mounting concerns around profitability, with the company still loss-making and showing weak multi-year revenue growth.
BAK shares fell roughly 11% in the latest trading session, marking a sharp single-day drop for the Brazilian petrochemical producer The decline comes amid persistent concerns about high leverage, a weaker credit profile, and soft petrochemical margins in a challenging macro environment for chemicals​
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.